US2004229948A1PendingUtilityA1

Method for preventing hepatic encephalopathic episodes

53
Priority: Apr 12, 2002Filed: Dec 1, 2003Published: Nov 18, 2004
Est. expiryApr 12, 2022(expired)· nominal 20-yr term from priority
Inventors:Marshall L. SummarSharron Gargosky
A61K 31/192A61K 31/19A61K 31/216A61K 31/715
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for preventing an initial hepatic encephalopathic episode in persons at risk for hepatic encephalopathic episodes by administering to the person a therapeutically effective amount of at least one phenyl butyrate compounds or a salt, derivative or metabolite of phenyl butyrate in a pharmaceutically acceptable vehicle.

Claims

exact text as granted — not AI-modified
I claim:  
     
         1 . A method of preventing an initial hepatic encephalopathic episode in a person at risk for hepatic encephalopathic episodes comprising administering to the person a therapeutically effective amount of at least one phenyl butyrate compound in a pharmaceutically acceptable vehicle, wherein the compound comprises one or more of the group consisting of phenyl butyrate, phenyl acetate, sodium benzoate, glyceryl-tri(4 phenyl butyrate), phenylbutyrylglutamines, phenylalkanes, phenylalkenes, and their acids, alcohols, salts, amines, esters, ethers, glycerides, salts, derivatives, and metabolites.  
     
     
         2 . The method of  claim 1 , wherein the compound is administered orally.  
     
     
         3 . The method of  claim 2 , wherein the compound is administered in an amount from about 0.1 to about 15 g/m 2  day.  
     
     
         4 . The method of  claim 2 , wherein the compound is administered in an amount from about 1 to about 8 g/m 2 /day.  
     
     
         5 . The method of  claim 2  wherein the compound is administered in an amount from about 3 to about 8 g/m 2 /day.  
     
     
         6 . The method of claims  2 ,  3 ,  4  or  5  wherein the compound comprises sodium phenyl butyrate.  
     
     
         7 . The method of claims  2 ,  3 ,  4  or  5  wherein the compound comprises glyceryl-tri(4 phenyl butyrate).  
     
     
         8 . The method of claims  2 ,  3 ,  4  or  5  wherein the compound comprises sodium benzoate.  
     
     
         9 . The method of claims  2 ,  3 ,  4  or  5  wherein the compound comprises sodium phenyl acetate.  
     
     
         10 . The method of claims  2 ,  3 ,  4  or  5  wherein the compound comprises sodium phenyl acetate and sodium benzoate.  
     
     
         11 . The method of  claim 1 , wherein the compound is delivered parentally.  
     
     
         12 . The method of  claim 11 , wherein the compound is administered in an amount of about 0.1 to about 15 g/m 2 /day.  
     
     
         13 . The method of  claim 11 , when an initial loading dose of the compound of about 2 to about 13 g/m 2  is additionally administered to the person.  
     
     
         14 . The method of  claim 11 , wherein the compound is administered in an amount of about 1 to about 8 g/m 2 /day.  
     
     
         15 . The method of  claim 11 , wherein the compound is administer in an amount of about 3 to about 8 g/m 2 /day.  
     
     
         16 . The method of claims  11 ,  12 ,  13 ,  14  or  15  wherein the compound comprises sodium phenyl butyrate.  
     
     
         17 . The method of claims  11 ,  12 ,  13 ,  14  or  15  wherein the compound comprises glyceryl-tri (4 phenyl butyrate).  
     
     
         18 . The method of claims  11 ,  12 ,  13 ,  14  or  15  wherein the compound comprises sodium benzoate.  
     
     
         19 . The method of claims  11 ,  12 ,  13 ,  14  or  15  wherein the compound comprises sodium phenyl acetate.  
     
     
         20 . The method of  claim 11 ,  12 ,  13 ,  14  or  15  wherein the compound comprises sodium phenyl acetate and sodium benzoate.  
     
     
         21 . A method of lessening severity of an initial hepatic encephalopathic episode in a person at risk for hepatic encephalopathic episodes comprising administering to the person a therapeutically effective amount of at least one phenyl butyrate compound in a pharmaceutically acceptable vehicle, wherein the compound comprises one or more of the group consisting of phenyl butyrate, phenyl acetate, sodium benzoate, glyceryl-tri(4 phenyl butyrate), phenylbutyrylglutamines, phenylalkanes, phenylalkenes, and their acids, alcohols, salts, amines, esters, ethers, glycerides, salts, derivatives, and metabolites and wherein the administering occurs before the hepatic encephalopathic episode.  
     
     
         22 . A method of delaying an initial hepatic encephalopathic episode in a person at risk for hepatic encephalopathic episodes comprising administering to the person a therapeutically effective amount of at least one phenyl butyrate compound in a pharmaceutically acceptable vehicle, wherein the compound comprises one or more of the group consisting of phenyl butyrate, phenyl acetate, sodium benzoate, glyceryl-tri(4 phenyl butyrate), phenylbutyrylglutamines, phenylalkanes, phenylalkenes, and their acids, alcohols, salts, amines, esters, ethers, glycerides, salts, derivatives, and metabolites and wherein the administering occurs before the hepatic encephalopathic episode.  
     
     
         23 . A method of lessening severity of a hepatic encephalopathic episode in a person at risk for hepatic encephalopathic episodes, wherein at least 12 weeks has passed since the person had a prior episode, comprising administering to the person a therapeutically effective amount of at least one phenyl butyrate compound in a pharmaceutically acceptable vehicle, wherein the compound comprises one or more of the group consisting of phenyl butyrate, phenyl acetate, sodium benzoate, glyceryl-tri(4 phenyl butyrate), phenylbutyrylglutamines, phenylalkanes, phenylalkenes, and their acids, alcohols, salts, amines, esters, ethers, glycerides, salts, derivatives, and metabolites and wherein the administering occurs before the hepatic encephalopathic episode.  
     
     
         24 . A method of delaying a hepatic encephalopathic episode in a person at risk for hepatic encephalopathic episodes, wherein at least 12 weeks has passed since the person had a prior episode, comprising administering to the person a therapeutically effective amount of at least one phenyl butyrate compound in a pharmaceutically acceptable vehicle, wherein the compound comprises one or more of the group consisting of phenyl butyrate, phenyl acetate, sodium benzoate, glyceryl-tri(4 phenyl butyrate), phenylbutyrylglutamines, phenylalkanes, phenylalkenes, and their acids, alcohols, salts, amines, esters, ethers, glycerides, salts, derivatives, and metabolites and wherein the administering occurs before the hepatic encephalopathic episode.  
     
     
         25 . A method of preventing a hepatic encephalopathic episode in a person at risk for hepatic encephalopathic episodes, wherein at least 12 weeks has passed since the person had a prior episode, comprising administering to the person a therapeutically effective amount of at least one phenyl butyrate compound in a pharmaceutically acceptable vehicle, wherein the compound comprises one or more of the group consisting of phenyl butyrate, phenyl acetate, sodium benzoate, glyceryl-tri(4 phenyl butyrate), phenylbutyrylglutamines, phenylalkanes, phenylalkenes, and their acids, alcohols, salts, amines, esters, ethers, glycerides, salts, derivatives, and metabolites and wherein the administering occurs before the hepatic encephalopathic episode.

Join the waitlist — get patent alerts

Track US2004229948A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.